Artelo Biosciences regains Nasdaq compliance; monitored for one year

ARTELO BIOSCIENCES, INC.

Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.
Subject to mandatory panel monitor through April 6, 2027; re-deficiency could trigger delisting.
CEO cites focus on ART27.13 (cancer cachexia) Phase 2 data, ART26.12 (neuropathic pain), and partnerships.
Common stock trades on Nasdaq under ticker ARTL.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.